Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Acute Ischemic Stroke with Atherosclerosis
NCT06083961Phase 4Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke comparing Alirocumab + Standard of Care with Standard of Care (2 arms). Primary endpoints: LDL change rate at Day 30 and Achievement rate to target LDL level at Day 30. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
alirocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06083961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083961.